| Título: | Erythrocytes as Carriers for Drugs and Contrast Agents |
| Autores: | Magnani, Mauro; Department of Biomolecular Sciences, University of Urbino, Urbino |
| Fecha: | 2014-01-24 |
| Publicador: | Central Asian Journal of Global Hearth |
| Fuente: |
 |
| Tipo: | |
| Tema: | No aplica |
| Descripción: | Erythrocytes, also known as Red Blood Cells (RBC), are typically used in transfusion medicine to replace lost blood in patients who underwent different kinds of medical treatments as well as those involved in accidents resulting in blood loss. In addition to these common uses, RBC are being used for a variety of new applications either as therapeutics or as diagnostics. Most of these novel approaches are made possible due to the peculiar properties of these cells. We have invented a technology that allows cells to be opened and resealed without affecting their main physiological characteristics with a minimal amount of patient blood. Uses of processed RBCs in biomedical engineering include work with drugs, biomedical compounds and/or nanomaterials. These constructs are a new armamentarium available to the physicians for the release of drugs in circulation, for targeting drugs to selected sites in the body, or for in vivo diagnostic procedures based on magnetic and/or optical methods. Autologous human RBC loaded with dexamethasone (EryDex), a common corticosteroid, have been used in the treatment of Cystic Fibrosis, Crohn’s Disease, and other severe inflammatory conditions. Benefits and safety of this technology have been documented in over 2,500 treatments. EryDel SpA is a company focused on developing and commercializing innovative therapies and diagnostics based on the use of autologous RBCs as agent carriers. More recently, EryDel SpA completed a Phase II Proof of Concept study in patients with Ataxia Telangiectasia (AT), a rare progressive neurological autosomal recessive disorder that leads to mortality in most patients at an early age, with significant benefit seen on primary and secondary end-points. EryDex treatment has received Orphan Drug Designation by EMA for the treatment of Cystic Fibrosis and both by EMA and FDA for the treatment of AT. The encapsulation of superparamagnetic nanoparticles within RBC has lead to the generation of new biomimetic constructs that now permits the use of these nanomaterials in vivo avoiding their rapid sequestration and their accumulation in unwanted districts (PCT WO 2008/003524 A3). Similarly, the encapsulation of infrared fluorescent agents into RBC gives opportunity to the measurement of vasomotion in the human retinal vasculature suggesting a possible correlation with retinal edema. In summary, the newly developed RBC-based drug delivery system is an innovative technology platform that could be used in a wide range of applications opening to unlimited new therapeutic approaches. Furthermore, the same system has been adapted to deliver contrasting agents within the body enabling the improvement of current fluorangiographic procedures and the imaging by Magnetic Resonance (MRI) and Magnetic Particle (MPI). EryDel S.p.A. has recently completed trials to bring EryDex treatment to the market and to implement the clinical applications of the RBC technology. |
| Idioma: | Inglés |
1 The Central Asian Journal of Global Health: A Supercourse Journal por Linkov, Faina; University of Pittsburgh,LaPorte, Ronald; University of Pittsburgh | 6 The HUPO Human Proteome Project (HPP), a Global Health Research Collaboration por Omenn, Gilbert S.; University of Michigan |
2 New directions in building a scientific social network: Experiences in the Supercourse project and application to Central Asia por Hennon, Meredith; University of Pittsburgh,LaPorte, Ronald E.; University of Pittsburgh,Shubnikov, Eugene; Institute of Internal Medicine, Novosibirsk, Russia,Linkov, Faina; University of Pittsburgh | 7 Keeping Up with the Times por Burambayeva, Valentina |
3 Modernization and growth in Kazakhstan por Sharman, Almaz; Nazarbayev University | 8 Public Health Challenges and Priorities for Kazakhstan por Aringazina, Altyn; Kazakhstan School of Public Health, Almaty, Republic of Kazakhstan,Gulis, Gabriel; University of Southern Denmark, Esbjerg, Denmark,Allegrante, John P.; Columbia University |
4 Missing Millions and Measuring Progress towards the Millenium Development Goals with a focus on Central Asian States por Carr-Hill, Roy; Centre for Health Economics,
University of York
YORK, YO10 5DD
UK | 9 Effects of Amyloid Beta Peptide on Neurovascular Cells por Askarova, Sholpan; Center for Life Sciences, Nazarbaev University,Tsoy, Andrey; Department of Biodiversity and Bioresources
71 Al-Farabi av. Biological Faculty Building
Al-Farabi Kazakh National University,Shalakhmetova, Tamara; Al-Farabi Kazakh National University, Biology Faculty, Almaty,Lee, James C-M; Department of Biological Engineering
240 Agricultural Engineering Building
University of Missouri - Columbia |
5 The Case of NRENs in Central Asia por Janz, Robert Franciscus; Centre for Information Technology,
University of Groningen,Kutanov, Askar; Academician, National Academy of Sciences, Kyrgyz Republic | 10 Is the Supercourse useful for Latin America? por Padilla-Raygoza, Nicolas; University of Guanajuato,Linkov, Faina; Division of Cancer Prevention and Population Science, University of Pittsburgh Cancer Institute,Shubnikov, Eugene; Institute of Internal Medicine, Novosibirsk, Russian Federation,LaPorte, Ronald E.; Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh Cancer Institute,Diaz-Guerrero, Rosalina; Departrment of Nursing and Obstetrics, Division of Health Sciences and Engineering, Campus Celaya Salvatierra, University of Guanajuato |